Our Vision

Harnessing Advanced Biomedical Signal Processing to Diagnose and Treat Disease

At BioSig Technologies, we are dedicated to developing new ways of diagnosing and treating disease based on our advanced signal processing capabilities. Our first product is the PURE EP™ System, a potentially game-changing solution aimed at the large and growing electrophysiology market.

Learn More About BioSig

BioSig Technologies Inc. Issues 2019 Shareholder Letter

Company provides updates on recent developments and highlights plans for future growth.

Press ReleaseFebruary 12, 2019

Mayo Clinic to Launch PURE EP™ First-in-Human Studies

BioSig has signed an agreement with Mayo Clinic to become the second leading institution to conduct first-in-human studies using the PURE EP™ System.

Press ReleaseDecember 6, 2018

BioSig Signs Agreement with TCAI for First-in-Human Studies

Texas Cardiac Arrhythmia Institute is set to begin first-in-human studies of BioSig’s advanced signal processing system.

Press ReleaseNovember 27, 2018

PURE EP™ System Receives FDA 510(k) Clearance

510(k) clearance from the U.S. Food and Drug Administration allows BioSig to proceed with plans for human testing and commercialization of the PURE EP™ System.

Press ReleaseAugust 14, 2018

Bioelectronic Medicine:
The Leading Edge of Healthcare

Bioelectronic medicine is a new, rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a wide range of diseases, from diabetes to depression.
BioSig aims to play a vital role in the field of bioelectronic medicine, based on our unique enabling technology and core competency in signal processing. Our initial focus is on heart disease and the fast-growing electrophysiology device market.

What Is Bioelectronic Medicine?

The Need to Improve Arrhythmia Treatment

Heart Disease Is the
#1 Cause of Death

Arrhythmia, a common cardiac condition, causes the heart to beat too quickly, too slowly, or erratically. New signal processing technologies could play a key role in enhancing outcomes from one of the most important treatments for arrhythmia: catheter ablation.

Challenging, Costly Conditions

The health and economic impacts of arrythmia are immense. The most common arrhythmia, atrial fibrillation (AFib), affects 33 million people worldwide – generating annual healthcare costs of $15,000 to $25,000 per patient.

Barriers to Treatment Efficacy

Treatment of AFib and VT typically starts with drug therapy, which is often ineffective, particularly in the later stages of heart disease. Catheter ablation fails as often as 60% of the time, leading to costly repeat procedures.

The Importance of Signal Clarity

Clearer signal information may help physicians work faster and more accurately during catheter ablation. The #1 reason for low ablation success rates is unreliable information – specifically, the inability to differentiate between the clean signal and lab noise.

PURE EP™: A Signal Processing Solution

By improving signal clarity, BioSig’s PURE EP™ System has the potential to deliver valuable advances in arrhythmia treatment. An independent product assessment by HRI, a leading healthcare market analysis firm, suggested that PURE EP™ may improve signal clarity and reduce noise, allow electrophysiologists to work more quickly and accurately, and reduce the need for repeat ablation procedures.

How Does Pure EP™ Work?

Key Scientific Publications

We’re proud of our high success rate for peer-reviewed publications: 9 of the 10 publications we’ve submitted to date have been accepted. These publications provide early evidence that PURE EP™ could offer valuable improvements in signal clarity and arrhythmia treatment.

Browse Our Publications

Looking Beyond Arrhythmia

In 2017, BioSig signed a 10-year strategic collaboration with experts at Mayo Clinic to jointly develop our signal processing technology. These experts see the potential for our technology to help them electrically map the entire body, possibly leading to treatments in other disease areas – for example, neurology and ophthalmology.

Learn About Our Partnerships

Creating Value for Investors

BioSig is a NASDAQ-traded company with a clear path to commercialization and growth, proven credentials for success, and a world-class leadership team. Check out our Investor Resources for financial and governance information, stock performance, SEC filings, and other materials.

See Investor Resources